Equillium (EQ) Non-Current Debt (2017 - 2023)
Equillium (EQ) posted quarterly Non-Current Debt of $1.8 million for Q1 2023, down 81.95% year-over-year from $10.2 million in Q1 2022, and down 79.54% quarter-over-quarter from $9.0 million in Q4 2022.
Equillium (EQ) Non-Current Debt (2017 - 2023) Analysis & Trends
Equillium (EQ) has reported Non-Current Debt for 7 consecutive years, with $1.8 million the latest figure, recorded in Q1 2023.
- In Q1 2023, Non-Current Debt fell 81.95% year-over-year to $1.8 million; the TTM figure through Mar 2023 stood at $1.8 million (down 81.95% YoY), while the FY2022 annual figure was $9.0 million, down 11.76% from the prior year.
- Non-Current Debt slipped to $1.8 million in Q1 2023 per EQ's latest filing, from $9.0 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $10.3 million in Q2 2022 and bottomed at $1.8 million in Q1 2023.
- Historically, Non-Current Debt has averaged $8.7 million across 5 years, with a median of $9.7 million in 2019.
- Annual changes were most pronounced in 2019 — Non-Current Debt soared 654.32% — and 2023, when it plunged 81.95%.
- Equillium's Non-Current Debt stood at $9.7 million in 2019, then rose by 2.06% to $9.9 million in 2020, then gained by 3.03% to $10.2 million in 2021, then dropped by 11.76% to $9.0 million in 2022, then sank by 79.54% to $1.8 million in 2023.
- Business Quant data shows EQ's Non-Current Debt at $1.8 million in Q1 2023, $9.0 million in Q4 2022, and $4.6 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 1.84 Mn |
| Dec 31, 2022 | 9.00 Mn |
| Sep 30, 2022 | 4.62 Mn |
| Jun 30, 2022 | 10.30 Mn |
| Mar 31, 2022 | 10.20 Mn |
| Dec 31, 2021 | 10.20 Mn |
| Sep 30, 2021 | 8.87 Mn |
| Jun 30, 2021 | 10.10 Mn |
| Mar 31, 2021 | 7.51 Mn |
| Dec 31, 2020 | 9.90 Mn |
| Sep 30, 2020 | 9.04 Mn |
| Jun 30, 2020 | 9.81 Mn |
| Mar 31, 2020 | 9.75 Mn |
| Dec 31, 2019 | 9.70 Mn |
| Sep 30, 2019 | 9.62 Mn |
| Sep 30, 2018 | 1.27 Mn |
| Dec 31, 2017 | 1.06 Mn |